CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anadys Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anadys Pharmaceuticals, Inc.
3115 Merryfield Row
Phone: (858) 530-3600p:858 530-3600 San Diego, CA  92121  United States Ticker: ANDSANDS

This company was Merged or Acquired on 11/23/2011.
This company ceased filing statements with the SEC on 12/6/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201112/31/2010YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer Stephen T.Worland 53 11/23/2011 3/1/2001
Senior Vice President - Research, Chief Scientific Officer James R.Appleman 54 1/6/2011 1/6/2011
Senior Vice President - Legal Affairs and General Counsel Elizabeth E.Reed 40 8/1/2009 10/1/2001
5 additional Officers and Directors records available in full report.

Business Names
Business Name
ANADYS PHARMACEUTICALS INC
ANDS

General Information
Number of Employees: 25 (As of 9/30/2011)
Outstanding Shares: 57,438,114 (As of 10/28/2011)
Shareholders: 5,400
Stock Exchange: NASD
Federal Tax Id: 223193172
Fax Number: (858) 527-1540


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023